CTOs on the Move

Advantia Health

www.advantiahealth.com

 
Advantia is transforming healthcare for all women - we`re setting a higher standard of care and convenience while reducing unnecessary costs. Compassion and value inspire everything we do. We take time to listen, answer questions completely, and offer helpful technology between visits so that our patients are empowered and at ease. Alongside coordinated care, Advantia is pioneering care models that align incentives with the best interests of women and their families.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Advantia Health raised $45M on 01/08/2020

Similar Companies

United Resource Networks

United Resource Networks is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sampling Technologies - STI Smart Technologies

Sampling Technologies - STI Smart Technologies is a Lower Sackville, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hello Phoenix

Hello Phoenix is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VetnCare

VetnCare is a collective of AAHA accredited animal hospitals located in Northern California that believe the highest standard of veterinary care comes from veterinarian owned hospitals, led by their clinical teams.

Ampio Pharmaceuticals

Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates.  These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending.  Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™.  The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.  Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema.  Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.